Patent Yard Sign in
Canadian application, no grantCanada

Adjuvant combination formulations

CA 2767116 A1 · Owner: Zoetis Whc 2 Llc · Inventors: Hagen, Michael

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof in combination with a cytokine or , lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to , enhance the immune response in a vertebrate host to a selected antigen.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed May 12, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 12, 2020.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 12, 2022.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMay 12, 2000
GrantedNo grant recorded
Term endedMay 12, 2020
Patent numberCA 2767116 A1
Classification (IPC)A61K39/39 +2 more

Timeline

Timeline From CIPO dates

2001200320052007200920112013201520172019Application filedMay 12, 2000Term endedMay 12, 2020

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.